TP53 and cancer: Intriguingly, we found that the expression of Trp53 was sustained in DNMT3L-treated MEFs (Supplementary Figure S7), which indicated that the restored proliferation ability of DNMT3L-treated MEFs was unlikely due to the “silencing of Trp53” that is frequently found in cancers.